# A Study of Cytisinicline for Vaping Cessation in Adult Smokers

> **NCT05431387** · PHASE2 · COMPLETED · sponsor: **Achieve Life Sciences** · enrollment: 160 (actual)

## Conditions studied

- Vaping
- E-Cig Use

## Interventions

- **DRUG:** cytisinicline
- **DRUG:** Placebo
- **BEHAVIORAL:** Behavioral support

## Key facts

- **NCT ID:** NCT05431387
- **Lead sponsor:** Achieve Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-13
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05431387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05431387, "A Study of Cytisinicline for Vaping Cessation in Adult Smokers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05431387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*